GI Innovation-GI Cell Signs MOU with Yonsei Medical Center to Establish Cell Therapy Center

[Asia Economy Reporter Chunhee Lee] GI Innovation announced on the 3rd that it signed a memorandum of understanding (MOU) on the 2nd to establish a cell therapy center for the production of advanced biopharmaceuticals, together with its affiliate GI Cell and Yonsei Medical Center.

The signing ceremony was held with the attendance of Myungho Jang, Chairman of GI Innovation, Chunpyo Hong, CEO of GI Cell, and Dongseop Yoon, Director of Yonsei Medical Center. Through this agreement, GI Innovation and GI Cell plan to enhance their capabilities in producing advanced biopharmaceuticals by collaborating with Yonsei Medical Center to establish GMP facilities at Severance Hospital and Songdo Severance Hospital (tentative name). Additionally, they will jointly conduct research, utilize research facilities and equipment, and hold academic conferences and seminars necessary for the development of advanced biopharmaceuticals such as cell therapies, protein new drugs, and antibody drugs.

Accordingly, it is expected that the collaboration among the three institutions?GI Innovation, which has new drug development capabilities; GI Cell, which possesses immune cell culture technology; and Yonsei Medical Center, which has clinical, medical, and research capabilities?will enable the establishment of a 'seamless process' for innovative cell therapy research, production, clinical trials, and regulatory approval.

Myungho Jang, Chairman of GI Innovation, stated, “By establishing GMP facilities for advanced biopharmaceutical production at Severance Hospital, we have secured a forward base to offer hope to terminal cancer patients who no longer have treatment options,” and added, “We will do our best to maximize innovative outcomes and efficiency through close mutual cooperation.”

Chunpyo Hong, CEO of GI Cell, said, "The establishment of an integrated cell and gene therapy production center by Yonsei Medical Center and GI Group has created an opportunity to accelerate clinical and research activities," and added, "We will continue to actively strive to create a sustainable growth platform through joint cooperation."

Director Dongseop Yoon of Yonsei Medical Center also said, “This agreement is a stepping stone for overcoming intractable diseases,” and added, “By implementing an industry-academia cooperation model where drug development, production, and clinical application are organically connected, we will create opportunities for the advancement of not only each institution but also the entire domestic bioindustry.”

This content was produced with the assistance of AI translation services.